• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia
Clin Lymphoma Myeloma Leuk. 2023 May 11:S2152-2650(23)00140-4. doi: 10.1016/j.clml.2023.04.012. Online ahead of print.ABSTRACTTreatment outcomes for children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) remained poor despite the use of intensive chemotherapy, imatinib or dasatinib, and consolidative allogeneic hematopoietic cell transplantation. Oleverembatinib, a third-generation ABL inhibitor, was found to be highly effective and safe in adults with chronic myeloid leukemia and in some adults with relapsed or refractory Ph+ ALL. We reviewed the efficacy and safety profile of olverembatin...
Source: Clinical Lymphoma and Myeloma - June 10, 2023 Category: Cancer & Oncology Authors: Xiaolan Li Jingliao Zhang Fang Liu Tianfeng Liu Ranran Zhang Yumei Chen Ye Guo Yongjun Fang Xiaojun Xu Ching-Hon Pui Xiaofan Zhu Source Type: research

Drug-Drug Interaction of Letermovir and Atorvastatin in Healthy Participants
Clin Pharmacol Drug Dev. 2022 Feb 14. doi: 10.1002/cpdd.1071. Online ahead of print.ABSTRACTLetermovir (MK-8228/AIC246) is a cytomegalovirus (CMV) DNA terminase complex inhibitor for CMV prophylaxis in adult patients undergoing hematopoietic stem cell transplant. It is cytochrome P450 (CYP) 3A inhibitor and inhibits organic anion transporting polypeptide 1B1/3 and breast cancer resistance protein transporters. Atorvastatin (ATV), a commonly used treatment for hypercholesterolemia, is a substrate of organic anion transporting polypeptide 1B1, potentially breast cancer resistance protein, and CYP3A. As letermovir may be coad...
Source: Clinical Genitourinary Cancer - February 14, 2022 Category: Cancer & Oncology Authors: Jacqueline B McCrea Karsten Menzel Adedayo Adedoyin Carolyn R Cho Sabrina Fox-Bosetti Sreeraj Macha Tian Zhao Fang Liu Deborah Panebianco S Aubrey Stoch Marian Iwamoto Source Type: research

Cancers, Vol. 11, Pages 1300: Assessing Cachexia Acutely after Autologous Stem Cell Transplant
ncey Jose M. Garcia Autologous hematopoietic stem cell transplantation (AHCT) is an accepted strategy for various hematologic malignancies that can lead to functional impairment, fatigue, muscle wasting, and reduced quality of life (QOL). In cancer cachexia, these symptoms are associated with inflammation, hypermetabolism, and decreased anabolic hormones. The relative significance of these factors soon after AHCT setting is unclear. The purpose of this study was to characterize the acute effects of AHCT on physical function, body composition, QOL, energy expenditure, cytokines, and testosterone. Outcomes were assesse...
Source: Cancers - September 3, 2019 Category: Cancer & Oncology Authors: Lindsey J. Anderson Chelsea Yin Raul Burciaga Jonathan Lee Stephanie Crabtree Dorota Migula Kelsey Geiss-Wessel Haiming M. Liu Solomon A. Graf Thomas R. Chauncey Jose M. Garcia Tags: Article Source Type: research